GSN and ovarian serous cystadenocarcinoma: Conversely, in 17 malignancies: BLCA, BRCA, CESC, COAD, esophageal carcinoma (ESCA), HNSC, KIRP, LUAD, LUSC, ovarian serous cystadenocarcinoma (OV), PRAD, READ, skin cutaneous melanoma (SKCM), STAD, THCA, UCEC and uterine carcinosarcoma (UCS), GSN expression was downregulated contrasted with in healthy tissue (p < 0.05; Figure 1B).